Oclacitinib Maleate | USP/EP-Certified JAK1 Inhibitor | Bulk API for Veterinary Dermatology
Google Keywords: Oclacitinib Maleate bulk supplier, JAK1 inhibitor API, pet allergy treatment, USP-certified veterinary drug
🌟 Product Overview
Oclacitinib Maleate (CAS 1208319-27-0), also known as PF-03394197, is a selective Janus kinase 1 (JAK1) inhibitor widely used in veterinary medicine to treat allergic dermatitis and pruritus in dogs. It modulates cytokine signaling to reduce inflammation and itching, offering rapid symptom relief.
✔️ Key Advantages
High Purity: ≥99% HPLC purity compliant with USP/EP standards.
Bulk Availability: Custom batches from 1g to 25kg with COA, MSDS, and stability data.
Formulation Flexibility: White crystalline powder soluble in DMSO (≥20 mg/ml) for oral or topical use.
🏥 Applications
Canine Allergic Dermatitis: First-line therapy for controlling itching and skin inflammation.
Veterinary Pharmaceuticals: Key ingredient in commercial antipruritic medications.
Research: Reference standard for JAK1 pathway studies in immunology.
📜 Quality Compliance
Certified under USP/EP guidelines with residual solvents <10ppm and heavy metals <20ppm.
Stability tested for 24 months at -20°C in airtight, light-resistant packaging.
📈 Market Trends
The global veterinary dermatology market is projected to grow at 6.5% CAGR (2025-2030), driven by rising demand for targeted therapies like Oclacitinib Maleate. Its selective JAK1 inhibition ensures efficacy with minimal systemic side effects.
China
